Japanese quality system measures
This article was originally published in The Gray Sheet
Executive Summary
Device firms selling in Japan should be aware that transitional quality system measures under Japanese Good Manufacturing Practice regulations will come into effect in April, according to Amanda Pack, senior project engineer and lead auditor for Underwriters Laboratories. Manufacturers pursuing certification of Class I and some Class II devices by a third party in Japan will have to adhere to the new manufacturing standards to receive a five-year certificate for their devices, but those firms that already have certifications will only have to adhere to the new standards when they apply for recertification, Pack said. Speaking during a Feb. 15 Regulatory Affairs Professionals Society webcast update on Japan regulatory practices, she noted that the transitional measures include review protocol, risk management, design and development protocol and others. Enacted under the Pharmaceutical Affairs Law in April 2005, the JGMP is similar to ISO 134859, the international quality systems standard (1"The Gray Sheet" Jan. 16, 2006, p. 8)...
You may also be interested in...
Firms Marketing In Japan Should Plan For License Renewals Under New Law
Device manufacturers that obtained a Japanese marketing license ("kyoka") in Japan before the revised Pharmaceutical Affairs Law (PAL) went into effect last April should allow time to come into compliance before the license expires, according to Steve McRoberts, global principal engineer at Underwriters Laboratories
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.